指南与共识支持与姑息治疗

癌症相关贫血的促红细胞生成素治疗管理:ASCO/ASH临床实践指南更新

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.
指南 / 共识 · J Clin Oncol · 2019-04-10

本指南更新了ASCO/ASH关于促红细胞生成素(ESA)用于癌症患者贫血的推荐。基于PubMed和Cochrane图书馆检索的随机对照试验及荟萃分析,专家组建议ESA(包括生物类似药)可用于化疗相关贫血且癌症治疗非根治性、血红蛋白<10 g/dL的患者;非化疗相关贫血患者除部分骨髓增生异常综合征外不应使用ESA;治疗期间血红蛋白升至避免输血所需的最低浓度即可;补铁可能改善血红蛋白反应并减少输血。

要点

  • ESA(包括生物类似药)可考虑用于化疗相关贫血、癌症治疗非根治性且血红蛋白<10 g/dL的患者,红细胞输注也是选择。
  • 除部分骨髓增生异常综合征患者外,非化疗相关贫血患者不应使用ESA。
  • ESA治疗期间血红蛋白可升至避免输血所需的最低浓度;补铁可能改善血红蛋白反应并减少红细胞输注。

核心结论

  • ESA(包括生物类似药)可提供给化疗相关贫血、癌症治疗非根治性且血红蛋白<10 g/dL的患者;红细胞输注也是选项。
  • 除部分骨髓增生异常综合征患者外,非化疗相关贫血患者不应使用ESA。
  • ESA治疗期间血红蛋白可升至避免输血所需的最低浓度。
  • 补铁可能用于改善接受ESA(伴或不伴缺铁)患者的血红蛋白反应并减少红细胞输注。

研究设计与样本

  • ASCO和ASH召集专家组,检索PubMed和Cochrane图书馆2010年1月31日至2018年5月14日发表的癌症患者随机对照试验和荟萃分析,并修订既往推荐。
  • 生物类似药ESA的文献检索扩大至癌症或慢性肾脏病患者的荟萃分析和随机对照试验以及癌症患者的队列研究。

主要发现

  • 主要文献回顾纳入15项随机对照试验的荟萃分析和2项随机对照试验。
  • 越来越多证据提示,在ESA治疗基础上加用铁可能改善造血反应并降低红细胞输注的可能性。
  • 生物类似药文献回顾提示,促红细胞生成素α的生物类似药与参照产品具有相似疗效和安全性,但癌症领域的证据仍有限。

关键数值与推荐

  • ESA(包括生物类似药)可提供给化疗相关贫血、癌症治疗非根治性且血红蛋白<10 g/dL的患者;红细胞输注也是选项。
  • 除部分骨髓增生异常综合征患者外,非化疗相关贫血患者不应使用ESA。
  • ESA治疗期间血红蛋白可升至避免输血所需的最低浓度。
  • 补铁可能用于改善接受ESA(伴或不伴缺铁)患者的血红蛋白反应并减少红细胞输注。

临床怎么用

  • 对化疗相关贫血、癌症治疗非根治性且血红蛋白<10 g/dL的患者,可考虑ESA(包括生物类似药)或红细胞输注。
  • 除部分骨髓增生异常综合征患者外,非化疗相关贫血患者不应使用ESA。
  • ESA治疗期间血红蛋白升至避免输血所需的最低浓度即可;可考虑补铁以改善血红蛋白反应并减少输血。

局限性

  • 生物类似药在癌症领域的证据仍有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. METHODS: PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in patients with cancer or chronic kidney disease and cohort studies in patients with cancer due to limited RCT evidence in the cancer setting. ASCO and ASH convened an Expert Panel to review the evidence and revise previous recommendations as needed. RESULTS: The primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and reduce the likelihood of RBC transfusion. The biosimilar literature review suggested that biosimilars of epoetin alfa have similar efficacy and safety to reference products, although evidence in cancer remains limited. RECOMMENDATIONS: ESAs (including biosimilars) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to < 10 g/dL. RBC transfusion is also an option. With the exception of selected patients with myelodysplastic syndromes, ESAs should not be offered to most patients with nonchemotherapy-associated anemia. During ESA treatment, hemoglobin may be increased to the lowest concentration needed to avoid transfusions. Iron replacement may be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESA with or without iron deficiency. Additional information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/guidelines .

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bohlius J, Bohlke K, Castelli R, et al. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol. 2019. PMID: 30969847. doi:10.1200/JCO.18.02142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。